INTRODUCTION AND OBJECTIVES: Induction of endoplasmic reticulum (ER) stress is a novel strategy used to treat malignancies. The novel proteasome inhibitor ixazomib kills cancer cells by causing unfolded protein accumulation and thereby inducing ER stress, but its efficacy as a single agent is limited especially in solid tumors. Cobicistat is a potent inhibitor of the intracellular drug-degrading enzyme CYP3A and we postulated that combining cobicistat with ixazomib would kill renal cancer cells by inducing ER stress effectively.
INTRODUCTION AND OBJECTIVES: Induction of endoplasmic reticulum (ER) stress is a novel strategy used to treat malignancies. The novel proteasome inhibitor ixazomib kills cancer cells by causing unfolded protein accumulation and thereby inducing ER stress, but its efficacy as a single agent is limited especially in solid tumors. Cobicistat is a potent inhibitor of the intracellular drug-degrading enzyme CYP3A and we postulated that combining cobicistat with ixazomib would kill renal cancer cells by inducing ER stress effectively.
METHODS: Renal cancer cells (769-P, 786-O, Caki-1) were treated with cobicistat (10-40 µM) and ixazomib (25-200 nM) . Cell viability and clonogenicity were assessed by MTS assay and colony formation assay. Flow cytometry was used for cell cycle analysis and annexin V assay. Western blotting was used to evaluate the induction of ER stress and the expression of apoptosis-associated proteins, cell cycle-associated proteins, NOXA, acetylated histone, and the autophagy marker light chain (LC) 3-II. Combination indexes were calculated by the Chou-Talalay method.
RESULTS: The combination of cobicistat and ixazomib inhibited cancer cell growth synergistically (combination indexes < 1) and suppressed colony formation significantly (p < 0.05). The combination decreased the expression of cyclin D1 and cyclin-dependent kinase 4, leading to the accumulation of the cells in the sub-G1 fraction. Drastic increases in the number of annexin-V positive cells (up to 94.6%) and increased expression of cleaved poly(ADP-ribose) polymerase confirmed that the combination induced apoptosis. As expected, ixazomib induced ER stress in a dose-dependent fashion, and cobicistat enhanced this stress synergistically. Increased expression of NOXA confirmed that the combination-induced apoptosis was a result of ER stress. Furthermore, this ER stress induction was essential to the combination's cytotoxic action because inhibition of unfolded protein accumulation by the protein synthesis inhibitor cycloheximide markedly attenuated the combination-induced apoptosis. Interestingly, we also found that the cobicistat-ixazomib combination increased the expression of LC3-II, confirming that the unfolded protein accumulation due to the combination induced autophagy.
CONCLUSIONS: Cobicistat enhanced ixazomib's activity, and the combination inhibited renal cancer growth synergistically.
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MP21-19 THE ANTISENSE LONG NON-CODING MITOCHONDRIAL RNA(AS-NCMTRNA) INTERFERENCE WITH ANDES-1537 AS A NOVEL TREATMENT FOR RENAL CARCINOMA
Mariela Araya, Santiago, Chile; Francisca Guevara, Jaime Villegas, Luis Alarc on, Luis Burzio, Vincenzo Borgna*, Santiago, Chile INTRODUCTION AND OBJECTIVES: Renal cell carcinoma (RCC) is the seventh most common cancer in men. Patients with distant metastasis have a 5 year survival rate of <10%. Metastatic RCC is resistant to chemotherapy and radiotherapy, so treatments are focused on targeted therapies. We previously described components of a unique family of non-coding mitocondrial transcripts named ASncmtRNAs. These transcripts are expressed in normal proliferating cells, but are down-regulated in tumor cells of different origin.
We found that knocking down these transcripts in vitro with antisense oligonucleotide (ASO) induces selective death of several human and murine tumor cell lines without affecting viability of normal cells. The aim of this study was to evaluate in vitro and in vivo, the therapeutic value of silencing the ASncmtRNA with ASO in human cell lines/primary cultures and in A498 xenograft and Patient derived xenograft (PDX) RCC model. METHODS: For the in vitro studies we used different human renal carcinoma cell lines (786-O, Caki-1, A498) and 6 primary cultures derived from RCC patients. Knock down of the ASncmtRNA was achieved by transfection of ASO targeted to the loop region of these transcripts (Andes-1537). As control, we used ASO with unrelated sequence (NR-ASO). Cell death was evaluated with FACS by PI and tripan exclusion assay and the decrease in tumorigenicity was determined by sphere assay. The apoptosis hallmarks evaluated were Caspase activation, DNA fragmentation and phosphatidylserine exposure on the outer membrane.
For the in vivo model 2,5x106 A498 cells were implanted subcutaneous in 10 NOD/SCID Balb/c mice. I. For the PDX mordel a 5mm3 tissue sample from a pT2N0M0 ISUP 3 RCC patient was implanted subcutaneosly in 10 NOD/SCID Balb/c mice ntraperitoneal treatments were performed every 48 hours for 6 times with Andes-1537 and NR-ASO (10 mg / kg). Necropsies were performed when the tumor reach 1000mm3 RESULTS: In vitro Andes-1537 treatment induces massive cell death by apoptosis (70-80%) at 48 hrs post-treatment. A significant inhibition of spheres was also observed.
In the A498 model the decrease in tumor growth was statistically significant in mice treated with Andes-1537 in comparison with NR-ASO (p.<0.05), in the PDX model the mean volume in the control group at 60 days was 1000mm3 and in Andes-1537 160mm3 CONCLUSIONS: These results support the potential use of Andes-1537 as a novel therapy for RCC.
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MP21-20 WHOLE-MOUNT PATHOLOGY OF RENAL TUMOR SPECIMENS IMPROVES THE DIAGNOSIS OF RENAL CANCER:THE PRELIMINARY RESULTS
Xiaozhi Zhao*, Xin Wang, Yao Fu, Qun Lu, Wenmin Cao, Bo Jiang, Hongqian Guo, Nanjing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Nephron sparing surgery is becoming the golden standard for small renal masses. Negative surgical margins is one of the important goals of nephron sparing surgery. Simple enucleation (SE) consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue, and large retrospective series have shown the oncological equivalence of SE and standard partial nephrectomy(PN). The oncological safety of this technique Still being questioned. The rate of positive margin varied from 1% to 7.5% from different center. A novel technique based on whole-mount serial sections enhances sampling while preserving specimen conformation and orientation. The aim of this study was to investigate assessment of margin status by the use of wholemount serial sections in renal tumor PN or TE specimens.
METHODS: All data were prospectively collected in institutional review board approved databases and analyzed retrospectively. Between June 2018 and October 2018, 59 consecutive evaluable patients treated with robotic assisted PN or TE were included in study. All the whole-mount serial sections for renal tumor specimens were evaluated by two dedicated pathologists and report the closest margin.The steps of whole mount section was shown in Figure 1 . Routinely available clinical and pathologic variables were also collected. RESULTS: For the 59 patients, 7 underwent PN, and the other 52 were treated by TE. The pathology showed 52 clear cell renal cell carcinoma, 3 papillary renal cell carcinoma, 2 chromophobe renal cell carinoma, 2 oncocytoma.In all cases the surgical margins were negative after PN, while in 1 (1.9%) patients of TE group there was surgical margin invasion of tumor, but the pathology showed oncocytoma. Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e299
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